**Biogen Breaks Ground on Kendall Common Headquarters in Cambridge, MA**
Biogen has officially broken ground on its new global headquarters at 75 Broadway in Cambridge, Massachusetts. This marks the first private development in MIT’s transformative three-million-square-foot Kendall Common project.
The new 16-story building will span approximately 580,000 square feet and serve as a consolidated location for Biogen’s currently scattered operations throughout the area. The biotech leader plans to relocate to the new site in 2028, coinciding with the company’s 50th anniversary.
“Helping to ensure that Biogen stays in Cambridge was very important to us,” said Patrick Rowe, Senior Vice President in MIT’s real estate group. “The company’s nearly 50-year history is a foundational component of the Kendall Square innovation ecosystem.”
Kendall Common is a 10-acre mixed-use development that, upon completion, will feature eight buildings designed for residential, office, lab, retail, and community uses. The project follows a decade-long review process and a federal agreement, which also led to the recent opening of the MIT-built John A. Volpe National Transportation Systems Center.
For industry leaders navigating shifting demographic trends, capital markets, development patterns, and the evolving requirements of healthcare real estate, Connect Healthcare Real Estate 2025 will provide valuable insights. The event is scheduled for October 14–15, 2025, in Irvine and aims to address the most pressing issues and opportunities in the sector.
Stay tuned for further updates on this major development and what it means for the future of biotechnology and innovation in greater Boston.
